A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-06-19) →
What happened
Orient Bio reported separate results for the fiscal year ended Mar 2026: revenue of US$19.9M (+1.2% year on year), an operating loss of US$2.77M and a net loss of US$1.39M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$19.9M |
|---|---|
| Revenue vs a year earlier | +1.2% |
| Operating profit | −US$2.77M |
| Net income | −US$1.39M |
| Period | the fiscal year ended Mar 2026 (separate) |
| Filed | 2026-05-15, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260515801062 → open original filing |
Versions of this filing
- 2026-05-15Original (this page)
- 2026-06-19Amendment 1
Source: DART. Information only, not investment advice.